Twist Bioscience (TWST) Is Down 5.1% After Upsized Equity Raise And Guidance Hike Has The Bull Case Changed?
Twist Bioscience (TWST) shares fell about 5.1% after the company completed a $300.0 million follow-on common stock offering at $96.00 per share. The firm reported Q3 2026 sales of $118.38 million and a net loss of $35.05 million, and raised full-year 2026 revenue guidance to $456.0 million to $457.0 million.
How this was made
The 30-second read
Why it matters
Traders can reassess the risk-reward of TWST by combining the new capital structure (dilution) with the updated revenue trajectory (guidance hike) and the stated need to improve margin progress.
Market read
The article frames TWST’s post-offering selloff as a dilution-versus-execution debate, anchored by the specific FY2026 revenue guidance range.
What to watch
Investors may be underweighting the gap between revenue growth and loss reduction, given the article cites continued net losses and the need to convert top-line gains into margin progress.
Background
Twist Bioscience is a synthetic DNA products company that remains meaningfully loss-making, and it recently executed a follow-on equity raise while updating FY2026 revenue guidance.
Ticker impact
Twist Bioscience completed a $300.0M follow-on offering and raised FY2026 revenue guidance to $456.0M-$457.0M, driving a 5.1% drop.
Near term, expect volatility as traders weigh dilution versus the credibility of the higher revenue path and margin progress.
The article provides concrete deal terms (offering size and price) and the updated revenue range, but it does not add new margin/profitability data beyond Q3 loss and revenue.
Market effects
Biotech financing conditions and investor tolerance for dilution may be tested, especially for synthetic DNA platform companies still loss-making.
Limited, primarily Nasdaq biotech sentiment rather than a broad US market driver.
Low, as the disclosed facts are company-specific and US-focused.
Counterpoint
The guidance hike could indicate improving commercial traction, and the $300M raise may reduce near-term financing pressure enough to support a re-rating despite dilution.
Key entities
- companyTwist Bioscience
Completed a $300.0M follow-on common stock offering and raised FY2026 revenue guidance to $456.0M-$457.0M.
- transactionTwist Bioscience common stock offering
Upsized follow-on offering at $96.00 per share, shortly after filing for a $250.0M raise.
